{"entity":{"id":"argenx","kind":"company","name":"argenx","aka":["argenx SE","Argenx"],"tldr":"argenx is a Belgian antibody company best known for efgartigimod in autoimmune disease; its cancer programme, the anti-CD70 antibody cusatuzumab for acute myeloid leukaemia, was returned by its partner in 2021.","summary":"argenx, based in Ghent with Dutch and US operations and listed on Euronext and Nasdaq, develops antibodies from its llama-derived SIMPLE Antibody platform. Its lead product efgartigimod is approved for myasthenia gravis and other autoimmune conditions. In cancer it developed cusatuzumab, an anti-CD70 antibody tested with azacitidine in acute myeloid leukaemia, which Janssen licensed in 2018 and handed back in 2021. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.argenx.com"},{"label":"ClinicalTrials.gov: trials led by argenx","url":"https://clinicaltrials.gov/search?lead=argenx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Argenx"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["cusatuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Ghent","country":"BE","companyType":"biotech","website":"https://www.argenx.com","stage":"public","investors":[],"funding":[]},"route":"/companies/argenx/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/"}]}}